Healthcare Industry News: Boston Scientific
News Release - April 27, 2011
Darren Spencer Joins Advanced Cardiac Therapeutics as Director of Sales and Clinical Affairs, EuropeBrings Expertise in Innovative New Technologies for Electrophysiology
LAGUNA BEACH, Calif.--(Healthcare Sales & Marketing Network)-- Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that Darren Spencer has joined the company as director of Sales and Clinical Affairs, Europe.
“Darren’s considerable expertise in the field of electrophysiology has been instrumental in launching a number of key new technologies in Europe, where he was involved in early clinical work and first global sales,” said Peter van der Sluis, CEO of Advanced Cardiac Therapeutics. "We are thrilled to welcome him to the ACT team and look forward to his contributions as we prepare to launch the TEMPASURE™ cardiac ablation catheter in Europe this summer.”
Mr. Spencer’s most recent role was as the UK and Ireland sales manager for Atritech, which was acquired this year by Boston Scientific. From 2007 to 2009, he was the UK manager for Ablation Frontiers Inc., which was acquired by Medtronic. He also served as territory manager for Cameron Health, Inc., and Endocardial Solutions, Inc., which was acquired by St. Jude in 2005. He also held roles with Medtronic and Prucka Inc. and began his career as a cardiac specialist with Glenfield General Hospital in Leicester.
Advanced Cardiac Therapeutics’ TEMPASURE cardiac ablation catheter is the world’s first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology. The TEMPASURE system is designed to result in better outcomes for patients by reducing overall procedure time and increasing therapeutic effectiveness, while avoiding rare but serious adverse events. The system’s novel passive sensing microwave radiometry technology allows the electrophysiologist to measure the temperature of cardiac tissue at three millimeters depth during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control.
About Cardiac Arrhythmias
Cardiac arrhythmias occur when the electrical impulses in the heart don't work properly, causing the heart to beat too fast, too slowly or irregularly. Atrial fibrillation and atrial flutter are fast cardiac arrhythmias that can be life-threatening.
About Cardiac Catheter Ablation
Cardiac catheter ablation procedures are used to treat a variety of cardiac arrhythmias including atrial fibrillation and atrial flutter. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue in order to prevent the spread of electrical signals that give rise to the arrhythmia. The temperature of the tissue during ablation is critical – lower temperatures are ineffective, and temperatures that are too high can result in dangerous over-heating. Saline irrigation ensures that lesions are created safely and are effective deeper inside the cardiac tissue. However, the inclusion of irrigation negates the effectiveness of conventional thermometry.
About the TEMPASURE Cardiac Ablation Catheter
ACT's technology enables, for the first time, measurement of tissue temperature with a saline-irrigated RF catheter. The TEMPASURE cardiac ablation catheter continuously measures temperature at three millimeters depth below the heart wall surface using VERITAS™ Technology, a proprietary microwave radiometry system. The TEMPASURE system is designed to improve patient outcomes by providing electrophysiologists with real-time validation information and greater control in lesion creation.
About Advanced Cardiac Therapeutics
Headquartered in Laguna Beach, Calif., privately held Advanced Cardiac Therapeutics, Inc. specializes in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology for the treatment of patients with cardiac arrhythmias. For more information visit www.actmed.net.
Source: Advanced Cardiac Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.